Zentalis Pharmaceuticals (NASDAQ: ZNTL)
Zentalis Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Zentalis Pharmaceuticals Company Info
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
News & Analysis
Why Shares of Zentalis Pharmaceuticals Dropped This Week
A rash of insider selling meant the stock gave back some of its gains from last week.
Is It Too Late to Jump In on Zentalis?
The company's share price has nearly tripled since its IPO less than two months ago. Is it too late to get in on the fun?
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.